Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.
Please log in to your account or sign up in order to add this asset to your watchlist.
MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.
Anterix has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
According to analysts' consensus price target of $63.00, Anterix has a forecasted upside of 43.4% from its current price of $43.94.
Anterix has received no research coverage in the past 90 days.
Anterix does not currently pay a dividend.
Anterix does not have a long track record of dividend growth.
In the past three months, Anterix insiders have sold 29,080.39% more of their company's stock than they have bought. Specifically, they have bought $4,264.00 in company stock and sold $1,244,252.00 in company stock.
Only 3.53% of the stock of Anterix is held by insiders.
82.68% of the stock of Anterix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings for Anterix are expected to grow in the coming year, from ($2.51) to ($1.12) per share.
The P/E ratio of Anterix is -16.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
The P/E ratio of Anterix is -16.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Anterix has a P/B Ratio of 4.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Anterix Inc. operates as a wireless communications company. The company focuses on commercializing its spectrum assets to enable the targeted utility and critical infrastructure customers to deploy private broadband networks, technologies, and solutions. It holds licensed spectrum in the 900 MHz band with coverage throughout the United States, Alaska, Hawaii, and Puerto Rico. The company was formerly known as pdvWireless, Inc. and changed its name to Anterix Inc. in August 2019. Anterix Inc. was incorporated in 1997 and is headquartered in Woodland Park, New Jersey.
ATEX Stock traded down $1.62 during trading on Friday, reaching $43.94. 74,594 shares of the company were exchanged, compared to its average volume of 74,245. The stock's 50 day moving average price is $42.56 and its 200 day moving average price is $49.31. Anterix has a 52-week low of $37.70 and a 52-week high of $66.55. The company has a market cap of $832.40 million, a P/E ratio of -16.46 and a beta of 0.55.
Anterix (NASDAQ:ATEX - Get Rating) last announced its quarterly earnings results on Friday, May 20th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.54). Anterix had a negative return on equity of 25.44% and a negative net margin of 3,957.07%. The firm had revenue of $0.34 million for the quarter, compared to analysts' expectations of $1.15 million. As a group, equities research analysts forecast that Anterix will post -2.51 EPS for the current year.
In other Anterix news, Chairman Morgan E. Obrien sold 25,000 shares of the company's stock in a transaction on Wednesday, June 15th. The stock was sold at an average price of $40.03, for a total value of $1,000,750.00. Following the sale, the chairman now owns 34,313 shares of the company's stock, valued at $1,373,549.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Anterix news, Chairman Morgan E. Obrien sold 25,000 shares of Anterix stock in a transaction dated Wednesday, June 15th. The shares were sold at an average price of $40.03, for a total transaction of $1,000,750.00. Following the completion of the transaction, the chairman now owns 34,313 shares in the company, valued at $1,373,549.39. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Gena L. Ashe sold 5,680 shares of the stock in a transaction that occurred on Wednesday, June 1st. The shares were sold at an average price of $42.87, for a total transaction of $243,501.60. Following the completion of the sale, the insider now owns 34,312 shares in the company, valued at $1,470,955.44. The disclosure for this sale can be found here. 3.53% of the stock is currently owned by insiders.
Sign-up to receive the latest news and ratings for Anterix and its competitors with MarketBeat's FREE daily newsletter.
Sign-up to receive the latest news and ratings for Anterix and its competitors with MarketBeat's FREE daily newsletter.
1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anterix in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ATEX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATEX, but not buy additional shares or sell existing shares. View ATEX analyst ratings or view top-rated stocks.
1 analysts have issued 1-year price objectives for Anterix's stock. Their ATEX share price forecasts range from $63.00 to $63.00. On average, they anticipate the company's share price to reach $63.00 in the next twelve months. This suggests a possible upside of 43.4% from the stock's current price. View analysts price targets for ATEX or view top-rated stocks among Wall Street analysts.
Anterix's stock was trading at $58.76 at the beginning of the year. Since then, ATEX stock has decreased by 25.2% and is now trading at $43.94. View the best growth stocks for 2022 here.
The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022. View our ATEX earnings forecast.
Anterix Inc. (NASDAQ:ATEX) posted its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.01. The company earned $0.18 million during the quarter, compared to analysts' expectations of $0.18 million. Anterix had a negative trailing twelve-month return on equity of 25.44% and a negative net margin of 3,957.07%. During the same quarter last year, the firm posted ($0.94) EPS.
Based on aggregate information from My MarketBeat watchlists, some companies that other Anterix investors own include Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Cisco Systems (CSCO), International Business Machines (IBM), Micron Technology (MU), Occidental Petroleum (OXY), Stericycle (SRCL) and Applied Optoelectronics (AAOI).
Anterix trades on the NASDAQ under the ticker symbol "ATEX."
Anterix's stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (1.45%), Clearbridge Investments LLC (1.32%), Northern Trust Corp (0.69%), PenderFund Capital Management Ltd. (0.67%), FMR LLC (0.60%) and Roubaix Capital LLC (0.56%). Insiders that own company stock include Brian Mcauley, Christopher Guttman-Mccabe, Elaine Gangeri, Gena L Ashe, Hamid Akhavan, Leslie B Daniels, Leslie B Daniels, Morgan E Obrien, Owl Creek Asset Management, L, Robert Harris Schwartz, Ryan Gerbrandt, Stephen Feinberg, Thomas Clark Akers and Timothy Gray. View institutional ownership trends.
Shares of ATEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
One share of ATEX stock can currently be purchased for approximately $43.94.
Anterix (NASDAQ:ATEX) has a market capitalization of $832.40 million and generates $1.08 million in revenue each year. The company earns $-37,520,000.00 in net income (profit) each year or ($2.67) on an earnings per share basis.
Anterix's mailing address is 3 GARRET MOUNTAIN PLAZA SUITE 401, WOODLAND PARK NJ, 07424. The official website for the company is www.anterix.com. The company can be reached via phone at (973) 771-0300, via email at nvecchiarelli@anterix.com, or via fax at 888-858-6245.
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.